Biocompatibility Study of Different Hyaluronan Products for Intra-articular Treatment of Knee Osteoarthritis

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2019 Sep 13

PMID 31511072

Citations 4

Authors

Keiji Yoshioka

Madoka Katayama

Takeo Nishiyama

Kohei Harada

Sawako Takeshita

Yuji Kawamata

Affiliations

Soon will be listed here.

Abstract

Background: Intra-articular (IA) injection of hyaluronic acid (HA) (IA-HA) is a well-recognized treatment option for pain associated with symptomatic knee osteoarthritis (OA). IA-HA products differ in their HA content, molecular weight, cross-linking, and source of HA. These differences are assumed to affect the biocompatibility of the IA-HA products once injected inside the knee joint.

Methods: In the present study, we investigated the biocompatibility of three multiple-injection IA-HA products available in the global market. These included SUPARTZ FX™, a medium range molecular weight HA derived from rooster comb (Avian-HA); ORTHOVISC®, a high range molecular weight HA obtained through biological fermentation (Bio-HA); and SYNVISC®, a high molecular weight cross-linked hyaluronan derived from rooster comb (Avian-CL-HA). Rabbit knee joint tissues were histologically and biochemically examined after IA injection of the products. Furthermore, we compared the amounts of impurities in the IA-HA products.

Results: IA injection of Avian-CL-HA into rabbit knee joints induced the aggregation of inflammatory cells, infiltration of eosinophils, and an increase in the number of cells in the synovial fluid. However, these effects were not seen in the Avian-HA and Bio-HA groups. The residual protein content and the contaminant levels of bacterial endotoxins were below the limit of quantitation in all HA products. Avian-CL-HA contained relatively a large amount of (1 → 3)-β-D-glucan, but this was below the lower limit of quantification in the other HA products.

Conclusions: The present results clearly demonstrate that the biocompatibility of Avian-HA is comparable to that of Bio-HA, and they were both considered to have a favorable safety profile for the treatment of symptomatic OA of the knee. However, immunostimulatory activity was observed after injection of Avian-CL-HA: this might be a result of its unique cross-linking structure and/or the considerable amount of (1 → 3)-β-D-glucan impurity present in the formulation.

Citing Articles

Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy.

Fiaschini N, Hanieh P, Ariaudo D, Cimino R, Abbate C, Romano E Pharmaceutics. 2025; 16(12.

PMID: 39771571 PMC: 11676977. DOI: 10.3390/pharmaceutics16121593.

Safety and effectiveness of intra-articular injection of a highly cross-linked hyaluronic acid, LBSA0103 (Synovian): Results from a post-marketing surveillance study in South Korea.

Kim J, Kim K, Park K, Park Y, Bae J, Seo Y PLoS One. 2023; 18(6):e0287222.

PMID: 37347765 PMC: 10287010. DOI: 10.1371/journal.pone.0287222.

Intra-articular Hyaluronic Acid Treatments for Knee Osteoarthritis: A Systematic Review of Product Properties.

Ferkel E, Manjoo A, Martins D, Bhandari M, Sethi P, Nicholls M Cartilage. 2023; 14(4):424-432.

PMID: 37314014 PMC: 10807741. DOI: 10.1177/19476035231154530.

Self-Healing of Hyaluronic Acid to Improve In Vivo Retention and Function.

Gilpin A, Zeng Y, Hoque J, Ryu J, Yang Y, Zauscher S Adv Healthc Mater. 2021; 10(23):e2100777.

PMID: 34601809 PMC: 8666142. DOI: 10.1002/adhm.202100777.

Insights from Real-World Analysis of Treatment Patterns in Patients with Newly Diagnosed Knee Osteoarthritis.

Dysart S, Utkina K, Stong L, Nelson W, Sacks N, Healey B Am Health Drug Benefits. 2021; 14(2):56-62.

PMID: 34267860 PMC: 8244737.

References

Zhang W, Nuki G, Moskowitz R, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010; 18(4):476-99. DOI: 10.1016/j.joca.2010.01.013. View

Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S . Positive (1-->3)-beta-D-glucan in blood components and release of (1-->3)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion. 2002; 42(9):1189-95. DOI: 10.1046/j.1537-2995.2002.00162.x. View

OGSTON A, STANIER J . The physiological function of hyaluronic acid in synovial fluid; viscous, elastic and lubricant properties. J Physiol. 1953; 119(2-3):244-52. PMC: 1392794. DOI: 10.1113/jphysiol.1953.sp004842. View

Garstang S, Stitik T . Osteoarthritis: epidemiology, risk factors, and pathophysiology. Am J Phys Med Rehabil. 2006; 85(11 Suppl):S2-11. DOI: 10.1097/01.phm.0000245568.69434.1a. View

Puttick M, Wade J, Chalmers A, Connell D, Rangno K . Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol. 1995; 22(7):1311-4. View

Goldberg V, Coutts R . Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop Relat Res. 2004; (419):130-7. DOI: 10.1097/00003086-200402000-00021. View

Waddell D, Bricker D . Hylan G-F 20 tolerability with repeat treatment in a large orthopedic practice: a retrospective review. J Surg Orthop Adv. 2006; 15(1):53-9. View

Nakao A, Yasui M, Kawagoe T, Tamura H, Tanaka S, Takagi H . False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology. 1997; 44(17):1413-8. View

Zardawi I, Chan I . Synvisc perisynovitis. Pathology. 2002; 33(4):519-20. DOI: 10.1080/00313020120083296. View

10.

. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000; 43(9):1905-15. DOI: 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P. View

11.

Altman R, Bedi A, Karlsson J, Sancheti P, Schemitsch E . Product Differences in Intra-articular Hyaluronic Acids for Osteoarthritis of the Knee. Am J Sports Med. 2015; 44(8):2158-65. DOI: 10.1177/0363546515609599. View

12.

Zhang W, Moskowitz R, Nuki G, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16(2):137-62. DOI: 10.1016/j.joca.2007.12.013. View

13.

Barton C, Vigor K, Scott R, Jones P, Lentfer H, Bax H . Beta-glucan contamination of pharmaceutical products: How much should we accept?. Cancer Immunol Immunother. 2016; 65(11):1289-1301. PMC: 5069311. DOI: 10.1007/s00262-016-1875-9. View

14.

Felson D . An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin North Am. 2004; 42(1):1-9, v. DOI: 10.1016/S0033-8389(03)00161-1. View

15.

Vos T, Flaxman A, Naghavi M, Lozano R, Michaud C, Ezzati M . Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2163-96. PMC: 6350784. DOI: 10.1016/S0140-6736(12)61729-2. View

16.

Chen A, Desai P, Adler E, Di Cesare P . Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee : a report of six cases. J Bone Joint Surg Am. 2002; 84(7):1142-7. View

17.

Altman R, Dasa V, Takeuchi J . Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis. Cartilage. 2017; 9(1):11-20. PMC: 5724672. DOI: 10.1177/1947603516684588. View

18.

Browder W, Williams D, Pretus H, Olivero G, Enrichens F, Mao P . Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg. 1990; 211(5):605-12; discussion 612-3. PMC: 1358234. View

19.

Schiavinato A, Finesso M, Cortivo R, Abatangelo G . Comparison of the effects of intra-articular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin Exp Rheumatol. 2002; 20(4):445-54. View

20.

. International Conference on Harmonisation; guidance on Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. Notice. Fed Regist. 2002; 65(251):83041-63. View